Tadalafil Associated With Anterior Ischemic Optic Neuropathy

Tadalafil (Cialis; Eli Lilly, Indianapolis, Ind) is used to treat erectile dysfunction.1 Sildenafil (Viagra; Pfizer, New York, NY), a similar medication, has been associated with nonarteritic anterior ischemic optic neuropathy (NAION).2,3 We describe a patient who developed NAION after he took tadalafil.

Report of a Case. A 59-year-old man with prostate cancer and erectile dysfunction underwent uncomplicated laparoscopic prostatectomy. His only other medical problem was depression, treated with buproprion hydrochloride. The immediate postoperative hematocrit measured 25.2%. The patient was ambulating and hemo dynamically stable on postoperative day 1 and that evening took 20 mg of tadalafil. Fifteen hours later, he reported dizziness lasting several minutes. Blood pressure and pulse measured 126/61 mm Hg and 99 bpm, respectively. The episode resolved spontaneously. Forty-five hours after ingesting tadalafil, he noted sudden, persistent “graying” in the inferior visual field of the left eye. The next day, he took 20 mg of tadalafil. The graying did not change.

Examination 6 days later revealed acuity of 20/20 OU, with a left relative afferent pupillary defect. Perimetry (Swedish Interactive Threshold Algorithm Standard 24-2) was normal in the right eye and showed inferior altitudinal loss in the left eye (Figure 1). The fundi were normal except for 2 cotton-wool spots in the macular right eye, left optic disc edema, and nerve fiber layer hemorrhage (Figure 2). The right optic disc was crowded. The remainder of the examination results were normal. Hematocrit measured 30.2%. Erythrocyte sedimentation rate and C-reactive protein levels were normal. He had no symptoms of temporal arteritis. Six weeks later, acuities and fields were unchanged in each eye, the left optic disc edema was resolving, and no cotton-wool spots were seen.

Comment. Nonarteritic anterior ischemic optic neuropathy developed 45 hours after taking tadalafil. Tadalafil, a phosphodiesterase type 5 inhibitor, enhances erection through smooth muscle relaxation and increased blood flow in the corpus cavernosum. Forty-five hours is within 2.5 half-lives for a drug that is effective for at least 36 hours, the latest time point tested in clinical trials.1 In this case, crowded optic discs and postoperative anemia were concurrent risk factors for NAION.4 However, the patient was mobile and asymptomatic prior to taking tadalafil.

Pomeranz et al5 published a case series of NAION associated with sildenafil, another phosphodiesterase type 5 inhibitor. Sildenafil lowers systemic blood pressure, which could contribute to NAION. The authors proposed that sildenafil might also contribute to NAION by vasodilation of the optic disc circulation and interference with vascular autoregulation. Tadalafil acts similarly but is more specific for phosphodiesterase type 5 (found in the corpus cavernosum) and has a longer half-life; also, tadalafil did not lower systemic blood pressure in clinical trials.1 Nonarteritic anterior ischemic optic neuropathy associated with tadalafil would more likely be due to a local effect on optic disc circulation.

Pomeranz et al5 suggested that patients with a history of unilateral NAION not use sildenafil. No definite association between tadalafil and NAION can be made on the basis of the current case. Similarly, the cotton-wool spots might have been related to anemia, tadalafil, or both. However, this case should heighten
awareness among ophthalmologists and physicians prescribing tadalafl, especially postoperatively. Further experience with tadalafl will provide data on the validity of an association with NAION.

George K. Escaravage, Jr, MD
John D. Wright, Jr, MD
Synde J. Givre, MD, PhD

Financial Disclosure: None.
Correspondence: Dr Givre, Department of Ophthalmology, University of North Carolina at Chapel Hill, 5100 Bioinformatics, CB#7040, Chapel Hill, NC 27599-7040 (givre@med.unc.edu).


**Recurrent Visual Field Defect and Ischemic Optic Neuropathy Associated With Tadalafl Rechallenge**

Tadalafl, a selective cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor, enhances penile erectile function in men. Nitric oxide along with cGMP promotes blood flow to and dilation of smooth muscle in the corpus cavernosum of the penis. Phosphodiesterase type 5 inhibitors prevent degradation of cGMP to potentiate erectile function. Tadalafl ([Cialis; Lilly ICOS LLC, Indianapolis, Ind]) is one of the PDE5 inhibitors approved for erectile dysfunction, which also include sildenafil citrate ([Viagra; Pfizer, Inc, New York, NY]) and vardenafl hydrochloride ([Levitra; Bayer AG, Leverkusen, Germany, and GlaxoSmithKline, Uxbridge, England]).

The package insert for tadalafl describes adverse ophthalmic reactions that include blurred vision, changes in color vision, conjunctivi-

vitis, eye pain, tearing, and swelling of the eyelids. Some reports suggest that sildenafil use may be associated with nonarteritic anterior ischemic optic neuropathy (NAION).\(^1\,^2\) We describe a patient who took tadalafl 5 times in 1 month. He developed transient inferior visual field loss in the right eye within 2 hours of taking the first 4 doses. After the fifth dose, he developed NAION in the right eye with persistent inferior visual field loss.

**Report of a Case.** A 67-year-old architect with a medical history of hypercholesterolemia sought care because of vision loss. His medications included atorvastatin calcium, aspirin, and folate. He took 20 mg of tadalafl for the first time one morning before sexual intercourse. Within 2 hours, he noted an isolated inferior visual field defect in the right eye that resolved by the time he awoke the following day. On 2 other occasions separated by several days each, he took 20 mg of tadalafl in the morning before sexual intercourse, followed by a similar inferior visual field defect in the right eye that resolved within 24 hours each time. Several days later, he did not achieve an erection after taking 20 mg of tadalafl, but a similar transient inferior visual field defect recurred. Three days later, he took a fifth dose of the drug and participated in sexual intercourse. He noted an inferior visual field defect in the right eye within 2 hours that failed to resolve. He denied systemic symptoms of giant cell arteritis. His erythrocyte sedimentation rate was 5 mm/h.

On examination 14 days later, visual acuities were 20/30 OD and 20/40 OS. His medical records demonstrated baseline acuities of 20/20 OD and 20/40 OS. A right afferent pupillary defect was present. He identified 10 of 10 Ishihara color plates with each eye. Humphrey visual fields showed an inferior alitudinal visual field defect in the right eye (Figure 1). Dilated fundus examination showed hyperemia and edema of the optic disc (Figure 2) consistent with NAION and a normal left optic disc with a small cup-disc ratio. The remainder of his neuro-ophtalmologic examination was unremarkable, including normal, nontender temporal artery pulses.

**Comment.** The most common optic neuropathy in patients older than 50 years is NAION. Examination results will show a swollen optic nerve and, typically, an alitudinal visual field defect. The pathophysiology underlying NAION is not well understood. Nearly all patients with NAION have a small, crowded optic nerve head (“disc at risk”),\(^4\) which leads some to believe that a type of compartment syndrome within the confines of the rigid scleral canal may occur.\(^5\) A microvascular ischemic event leads to axoplasmic stasis and edema,\(^6\) compressing the small capillaries of the optic nerve head. In older patients these capillaries may exhibit poor autoregulation, leading to more ischemia and axoplasmic stasis. The patient described herein had a disc at risk in the fellow eye, but it is unclear whether PDE5 inhibitors affect optic nerve blood flow.

Several patients have developed NAION between 45 minutes and 12 hours after taking sildenafil, a PDE5